- Stocks
- Pharma & Healthcare
- Take Solutions
Take Solutions share price
NSE: TAKEPharma & HealthcareBiotechnology
Take Solutions at a glance
Take Solutions (NSE: TAKE) closed at ₹11.31 on 22 Oct 2026, down 0.53% on the day. With a market capitalisation of ₹167 Cr, it ranks 2373rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
At its last close the stock traded at 39× trailing earnings, against a return on equity of 35.0% in FY26. Over the past year the share price has fallen 36.4%. Its 52-week range is ₹10.81 (22 Oct 2026) to ₹50.14 (20 Apr 2026); the last close is 77.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹54 Cr and net profit ₹4 Cr, on a consolidated basis. Promoters held 0.00% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹167 CrRank 2373 on NSE
- P/E (trailing)
- 39×
- Price to book
- 18.91×FY26
- EPS (TTM)
- ₹0.73to Q4 FY26
- ROE
- 35.0%FY26
- ROCE
- 15.4%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 20.0%FY26
- Book value / share
- ₹2.10FY26
- 52-week high
- ₹50.1420 Apr 2026
- 52-week low
- ₹10.8122 Oct 2026
- 1-year return
- −36.4%
- RSI (14-day)
- 34.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.53% | −1.3% | −31.4% | −45.2% | −36.4% |
Take Solutions quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | ₹54 Cr |
| Revenue YoY | — | — | — | — | — | — | — | — |
| Net profit | −₹4 Cr | −₹2 Cr | ₹48 Cr | −₹5 Cr | −₹1 Cr | ₹6 Cr | ₹1 Cr | ₹4 Cr |
| Net profit YoY | — | — | — | — | — | — | −97.7% | — |
| Net margin | — | — | — | — | — | — | — | 8.0% |
| EPS | −₹0.26 | −₹0.11 | ₹3.26 | −₹0.33 | −₹0.06 | ₹0.43 | ₹0.07 | ₹0.29 |
Take Solutions financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹774 Cr | ₹655 Cr | ₹189 Cr | ₹66 Cr | ₹0 Cr | — |
| Operating profit | −₹214 Cr | −₹85 Cr | −₹35 Cr | −₹25 Cr | ₹1 Cr | — |
| Net profit | −₹450 Cr | −₹782 Cr | −₹100 Cr | −₹120 Cr | ₹37 Cr | — |
| EPS (₹) | −₹31.00 | −₹54.00 | −₹7.00 | −₹8.00 | ₹3.00 | — |
| Cash from operations | ₹135 Cr | ₹30 Cr | ₹20 Cr | ₹9 Cr | −₹16 Cr | — |
| Total debt | ₹134 Cr | ₹15 Cr | ₹6 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹1,125 Cr | ₹181 Cr | ₹109 Cr | −₹9 Cr | ₹21 Cr | ₹31 Cr |
Take Solutions shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 53.41% | 53.34% | 5.19% | 0.00% | 0.00% | 0.00% |
| Foreign institutions | — | — | — | 0.56% | 0.29% | 0.21% |
| Non-institutions | 46.58% | 46.66% | 94.81% | 99.44% | 99.71% | 99.79% |
Take Solutions vs peers
The listed Pharma & Healthcare companies nearest to Take Solutions by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| BROOKSBrooks Laboratories | ₹60.49 | −0.03% | −51.8% | ₹178 Cr | 7.2 | — |
| BALPHARMABal Pharma | ₹109.58 | −2.16% | +28.9% | ₹174 Cr | 27.7 | — |
| MADHAVBAUGVaidya Sane Ayu | ₹161.10 | −4.11% | −43.1% | ₹169 Cr | — | — |
| MEDICOMedico Remedies | ₹20.40 | −1.92% | −58.2% | ₹169 Cr | 12.9 | — |
| TAKETake Solutions | ₹11.31 | −0.53% | −36.4% | ₹167 Cr | 39 | — |
| PANCHSHEELPanchsheel Org | — | — | — | ₹159 Cr | — | — |
| NATCAPSUQNatural Capsules | ₹150.00 | −2.47% | −34.8% | ₹156 Cr | — | — |
Ask anything about Take Solutions
Pivot answers on the live chart with evidence you can check, and tests strategies against TAKE's own history. Try: “Why has TAKE moved over the last three months?” · “Backtest a 50-day moving-average crossover on TAKE over five years” · “Compare TAKE with BROOKS on margins and valuation”
Frequently asked questions about Take Solutions
What is the share price of Take Solutions today?
Take Solutions (NSE: TAKE) last closed at ₹11.31 on 22 Oct 2026. Its 52-week high is ₹50.14 and its 52-week low is ₹10.81.
What is the market cap of Take Solutions?
Take Solutions' market capitalisation is ₹167 Cr (₹167 Cr) at the 22 Oct 2026 close, ranking 2373rd among the NSE companies Pivot tracks.
What is the P/E ratio of Take Solutions?
Take Solutions trades at a trailing P/E of 39. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 12.9.
What is the ROE and ROCE of Take Solutions?
Return on equity was 35.0% in FY26 and return on capital employed was 15.4% in FY26 (consolidated figures).
Is Take Solutions a debt-free company?
Take Solutions is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Take Solutions' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Take Solutions reported revenue of ₹54 Cr and net profit of ₹4 Cr.
How has Take Solutions stock performed over the last year?
Take Solutions' share price has fallen 36.4% over the past year, −45.2% over three months and −31.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Take Solutions?
As of 30 Jun 2026: promoters 0.00%, foreign institutions 0.21%, non-institutions 99.79%.
Who are Take Solutions' competitors?
The listed Pharma & Healthcare companies closest to Take Solutions by market cap are Brooks Laboratories, Bal Pharma, Vaidya Sane Ayu, Medico Remedies, Panchsheel Org and Natural Capsules.
Is Take Solutions a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Take Solutions' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TAKE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text